Eli Lilly just released Phase 3 data on retatrutide — a first-in-class GIP / GLP-1 / glucagon triple agonist. T2D patients lost up to 16.8% of body weight in 40 weeks. Earlier obesity + osteoarthritis trial showed an average 71.2 lb loss at 80 weeks. The TRIUMPH-1 obesity readout expected later this quarter could be the moment retatrutide overtakes tirzepatide as the top weight loss drug. Here is what the data actually shows — and why peptide-aware readers should care.
If you have been paying attention to the GLP-1 space, you already know tirzepatide (Mounjaro / Zepbound) raised the bar dramatically over semaglutide (Ozempic / Wegovy). The dual GIP + GLP-1 agonist delivered roughly 22% average weight loss in obesity trials, compared to 15% for semaglutide. That difference is the reason Mounjaro and Zepbound have eaten so much market share so fast.
Retatrutide is the next jump. It does not just add a third receptor — it adds glucagon, which sounds counterintuitive (glucagon raises blood sugar) but in this molecular context drives additional metabolic burn through increased energy expenditure. The result, based on data Lilly just released, is the highest weight loss numbers ever produced by an incretin-class drug. Here is what we know.
What Retatrutide Actually Is
Retatrutide is a single peptide molecule that binds and activates three different receptors simultaneously: GIP (gastric inhibitory polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon. This is what "first-in-class triple agonist" means — no other approved or late-stage compound hits all three.
| Spec | Detail |
|---|---|
| Class | GIP / GLP-1 / glucagon triple receptor agonist |
| Manufacturer | Eli Lilly & Company |
| Route | Subcutaneous injection, once weekly |
| Doses studied | 4mg, 9mg, 12mg |
| FDA status | Investigational — not yet approved |
| Earliest possible approval | Late 2026 / 2027 (regulatory submission expected after TRIUMPH-1 readout) |
Why a third receptor matters
Each receptor contributes a different metabolic effect. GIP and GLP-1 you already know — appetite suppression, slowed gastric emptying, insulin sensitivity. Glucagon is the new mechanism, and it is what differentiates retatrutide from tirzepatide.
Glucagon receptor activation increases basal energy expenditure — your body burns more calories at rest. It also stimulates lipolysis (fat breakdown for energy). When combined with GIP and GLP-1's appetite suppression, you get a compound that simultaneously reduces calorie intake AND increases calorie burn. That is why retatrutide is producing weight loss numbers that exceed what tirzepatide could deliver at any dose.
The Data: TRANSCEND-T2D-1 (March 2026)
This is the most recent data drop. The trial enrolled adults with type 2 diabetes — a population that historically struggles to lose weight on any treatment. Retatrutide hit the primary and all key secondary endpoints.
Headline numbers (40 weeks, highest dose group)
- HbA1c reduction: up to 2.0 percentage points (vs ~0.8 for placebo)
- Weight loss: 16.8% of body weight on the 12mg dose (efficacy estimand) — about 36.6 lbs average
- Treatment-regimen estimand (more conservative, includes dropouts): 15.3% weight loss at the highest dose vs 2.6% for placebo
- Cardiovascular markers: meaningful reductions in non-HDL cholesterol, triglycerides, and systolic blood pressure
The detail that matters most: No weight loss plateau was observed at 40 weeks. Patients were still losing weight when the trial ended. With tirzepatide and semaglutide, weight loss typically slows substantially after 6-8 months. Retatrutide may not.
Worth being precise about the comparison: in T2D specifically, retatrutide's HbA1c reduction (1.7 to 2.0 percentage points) is comparable to tirzepatide — not better. Where retatrutide pulled ahead was the weight loss component. Lilly's Chief Scientific Officer Daniel Skovronsky framed it as "glycemic control comparable to tirzepatide while delivering additional weight loss." For the diabetic population, that combination is the prize.
The Data: TRIUMPH-4 (December 2025)
This was actually retatrutide's first successful Phase 3 readout — and the headline number is striking. The trial enrolled adults with obesity (or overweight) plus knee osteoarthritis, a population dealing with the metabolic and mechanical consequences of weight together.
Headline numbers (80 weeks, treatment-regimen estimand)
- 9mg dose: 20.0% weight loss (50.5 lbs average)
- 12mg dose: 23.7% weight loss (60.0 lbs average)
- Per-protocol numbers: up to 71.2 lbs average loss at the highest dose
- Knee pain (WOMAC scale): reduced by up to 75.8% — more than 1 in 8 retatrutide patients reported being completely pain-free at the end of the trial
- Placebo comparison: 4.6% weight loss
The osteoarthritis angle here is significant. For decades, the medical establishment has told overweight knee patients to "lose weight first" — without offering tools that actually work. Retatrutide is the first weight loss drug to formally show meaningful structural pain relief in this population, opening a path for it to be prescribed not just for weight or diabetes but for joint disease secondary to obesity.
What's Coming: TRIUMPH-1 (Q2 2026)
The most consequential readout for the broader weight loss market is still ahead. TRIUMPH-1 is Lilly's pivotal Phase 3 obesity trial — the one that will support FDA submission for retatrutide as a weight loss drug in non-diabetic adults. The 80-week data is expected later this quarter.
Why it matters strategically: a clean TRIUMPH-1 readout would give retatrutide a credible claim to surpass tirzepatide as the most effective weight loss drug ever approved. That would reshape the prescription weight loss market — pharmaceutical analysts have called it the most important pipeline event Lilly has on the calendar this year.
What to watch in TRIUMPH-1: the percentage weight loss number (the Phase 2 data hinted at potentially 24%+ at higher doses), tolerability profile in non-diabetic patients (glucagon agonism could matter more here), and whether the no-plateau pattern from TRANSCEND-T2D-1 holds in a longer 80-week obesity study.
Side Effect Profile: What to Expect
Retatrutide's side effects look largely similar to other incretins — but with notable severity bumps at higher doses. From the TRANSCEND-T2D-1 data:
| Side Effect | 4mg | 9mg | 12mg |
|---|---|---|---|
| Nausea | 16.4% | 19.5% | 26.5% |
| Vomiting | (reported but lower) | (higher than 4mg) | (highest) |
| Diarrhea | Common | Common | Common |
From TRIUMPH-4 (the longer 80-week study), 9mg and 12mg nausea rates climbed to 38% and 43% respectively — meaningfully higher than what tirzepatide produces at peak dose. The pattern is clear: retatrutide is more effective, but the gut tolerability tax is also higher. This is the trade-off patients and prescribers will have to weigh.
Discontinuation rates due to side effects in TRIUMPH-4 were 12.2% (9mg) and 18.2% (12mg) compared to 4.0% on placebo. For context, tirzepatide's discontinuation rates run roughly 6-8% in obesity trials. Retatrutide is harder to stay on.
What This Means for the GLP-1 Space
Three things are worth thinking through.
1. The category will fragment by goal
If retatrutide wins approval with the kind of weight loss numbers it is showing, you will see a clearer split in the prescription weight loss market: semaglutide for the moderate-effect, lower-side-effect tier; tirzepatide for the workhorse middle; retatrutide for patients prioritizing maximum weight loss and willing to tolerate more aggressive gut effects. Each will have a real audience.
2. Side effect mitigation becomes more valuable
The same trend we covered with the BPC-157 + GLP-1 stack — practitioners pairing peptides like BPC-157 to soften gut side effects — will become more relevant, not less. Retatrutide's higher nausea profile means demand for tools that make these protocols tolerable will only grow.
3. Compounded retatrutide is coming
Whether or not the FDA formally approves it in the next 12 months, compounded retatrutide will appear in the gray market and at compounding pharmacies before the end of the year. Phase 3 data is sufficient signal for some practitioners to begin offering off-label combinations now. Quality and sourcing concerns will be even more acute than they have been with semaglutide compounds — the molecule is more complex and less broadly available in research-grade form.
Bottom Line
Retatrutide is producing the strongest weight loss numbers ever published in incretin-class research. 16.8% in T2D at 40 weeks. Up to 23.7% in obesity + osteoarthritis at 80 weeks. No plateau yet observed. Cardiovascular markers improved. Knee pain dramatically reduced.
The trade-off is tolerability — gut side effects are real, dose-dependent, and meaningfully higher than tirzepatide. Patients who can stay on it will lose more weight than any other approved or late-stage GLP-1 compound has produced. Patients who cannot will experience harsher onboarding than with tirzepatide.
The TRIUMPH-1 readout this quarter will be the moment we know whether retatrutide becomes the new top of the category. As of today, the data we have looks like the answer is yes — pending one more pivotal trial.
Want to understand how GIP, GLP-1, and glucagon receptors actually work together? The Peptide Academy Fundamentals course covers GLP-1 receptor pharmacology in Week 2 — including the mechanistic differences between semaglutide, tirzepatide, and the upcoming triple agonists. Free to start.